LGVN vs. ENSC, ARTL, SNGX, XCUR, THAR, EVOK, GTBP, REVB, ALZN, and PHIO
Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Ensysce Biosciences (ENSC), Artelo Biosciences (ARTL), Soligenix (SNGX), Exicure (XCUR), Tharimmune (THAR), Evoke Pharma (EVOK), GT Biopharma (GTBP), Revelation Biosciences (REVB), Alzamend Neuro (ALZN), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical preparations" industry.
Longeveron (NASDAQ:LGVN) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.
10.0% of Longeveron shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 24.3% of Longeveron shares are owned by insiders. Comparatively, 52.7% of Ensysce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Ensysce Biosciences has higher revenue and earnings than Longeveron. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
Longeveron presently has a consensus price target of $12.00, suggesting a potential upside of 809.09%. Ensysce Biosciences has a consensus price target of $7.00, suggesting a potential upside of 1,011.11%. Given Ensysce Biosciences' higher probable upside, analysts plainly believe Ensysce Biosciences is more favorable than Longeveron.
Longeveron has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.
In the previous week, Longeveron had 5 more articles in the media than Ensysce Biosciences. MarketBeat recorded 8 mentions for Longeveron and 3 mentions for Ensysce Biosciences. Longeveron's average media sentiment score of 1.08 beat Ensysce Biosciences' score of 0.18 indicating that Longeveron is being referred to more favorably in the media.
Longeveron received 5 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. Likewise, 88.89% of users gave Longeveron an outperform vote while only 60.00% of users gave Ensysce Biosciences an outperform vote.
Ensysce Biosciences has a net margin of -660.96% compared to Longeveron's net margin of -2,129.24%. Longeveron's return on equity of -300.96% beat Ensysce Biosciences' return on equity.
Summary
Longeveron beats Ensysce Biosciences on 9 of the 16 factors compared between the two stocks.
Get Longeveron News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longeveron Competitors List
Related Companies and Tools
